

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED  
CENTRAL FAX CENTER****SEP 25 2006**

Applicant : Christian von Corswant et al.  
Serial No. : 10/553,275  
Filing/371(c) Date : October 13, 2005  
For : New Non-Ionic Surfactants for Solubilizing  
Poorly Soluble Molecules  
Examiner : TBA  
Group Art Unit : 1625

<b>CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8</b> I hereby certify that this paper is being facsimile-transmitted to the U.S. Patent and Trademark Office on the date indicated below at the facsimile number 1-571-273-8300.	
Andrew Fessak	48,528
Name of Sender	PTO Reg. No.
<i>Andrew Fessak</i>	<i>9/25/06</i>
Signature	Date of Signature

**REQUEST FOR CORRECTED FILING RECEIPT**

Facsimile No: 1-571-273-8300  
Pages: 5 pages total

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CORRECTED FILING RECEIPT**

Sir:

I. Attached is a marked-up copy of the official Filing Receipt received from the PTO in the above-referenced application for which issuance of a corrected Filing Receipt is respectfully requested.

II. There is an error on the Filing Receipt with respect to the following data, which is incorrectly entered and/or omitted.

Serial No. 10/553,275, filed Oct. 13, 2005  
Docket No. 1103326-0798  
Page 2 of 2

<i>Error in</i>	<i>Correct data</i>
1. Applicant's name	1.
2. Applicant's address	2.
3. Title	3. The word "solubule" in the title should be amended to read "soluble".
4. Filing Date	4.
5. Publication Date	5.
6. Priority Data	6.
7. Continuing Data	7.
8. Power of Attorney	8.
9. Attorney Docket No.	9.

III. Applicant requests correction of the title as it appears in the PTO records. Specifically, the title should read --New Non-Ionic Surfactants for Poorly **Soluble** Molecules-- (correct) instead of "New Non-Ionic Surfactants for Poorly **Solubule** Molecules". The correct data is shown on the title page of the published PCT application, WO 2004/089869, which accompanied the application filing papers. A copy of the title page is attached to this paper.

- IV. ☒ The correction(s) is/are not due to any error by Applicant and no fee is due.  
☐ The requested correction is due to Applicant's error.

V. Issuance of a corrected Filing Receipt is respectfully requested. Any fee which may be due in connection with this communication should be charged to Deposit Account 23-1703.

Dated: Sept. 25, 2006

Respectfully submitted,

Andrew Fessak

Andrew Fessak

Reg. No. 48,528

Customer No. 007470

Agent's Direct Dial: (212) 819-8437

Attachments: Copy of Filing Receipt (2 pages)  
Copy of title page of published PCT appln. (WO 2004/089869) (1 page)



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22311-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/553,275	10/13/2005	1625	900	1103326-0798		19	2

7470  
WHITE & CASE LLP  
PATENT DEPARTMENT  
1155 AVENUE OF THE AMERICAS  
NEW YORK, NY 10036

WHITE & CASE LLP  
PATENT DEPARTMENT

SEP 15 2006

RECEIVED

CONFIRMATION NO. 6628

## FILING RECEIPT

\*OC000000020376538\*

Date Mailed: 09/13/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Christian von Corswant, Molndal, SWEDEN;  
Karl Hult, Stockholm, SWEDEN;  
Erik Soderlind, Molndal, SWEDEN;  
Fredrik Viklund, Stockholm, SWEDEN;

Power of Attorney: The patent practitioners associated with Customer Number **7470**.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/SE04/00572 04/13/2004

## Foreign Applications

SWEDEN 0301119-4 04/14/2003

If Required, Foreign Filing License Granted: 09/11/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/553,275**

Projected Publication Date: 12/21/2006

Non-Publication Request: No

Early Publication Request: No

Title

~~Non-ionic surfactants for solubilizing protein soluble molecules~~

soluble

RECEIVED  
CENTRAL FAX CENTER

SEP 25 2006

Preliminary Class

560

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stoptake.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
WO 2004/089869 A1

(51) International Patent Classification<sup>7</sup>: C07C 69/66,  
A61K 47/30, 47/14, C12P 7/62

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, ME, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/SE2004/000572

(22) International Filing Date: 13 April 2004 (13.04.2004)

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0301119-4 14 April 2003 (14.04.2003) SE

(71) Applicant (for all designated States except US): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CORSWANT,  
Christiaan von [SE/SE]; AstraZeneca R & D Mölndal,  
S-431 83 Mölndal (SE). HULT, Karl [SE/SE]; Kungliga  
Tekniska Högskolan, AlbaNova Universitetscentrum,  
Institutionen för bioteknologi, S-106 91 Stockholm  
(SE). SÖDERLIND, Erik [SE/SE]; AstraZeneca R & D  
Mölndal, S-431 83 Mölndal (SE). VIKLUND, Fredrik  
[SE/SE]; Kungliga Tekniska Högskolan, AlbaNova Uni-  
versitetscentrum, Institutionen för bioteknologi, S-106 91  
Stockholm (SE).

(74) Agent: ASTRAZENECA AB; Global Intellectual Prop-  
erty, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AB, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

## Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,  
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,  
LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG)

## Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NEW NON-IONIC SURFACTANTS FOR SOLUBILIZING POORLY SOLUBLE MOLECULES



(I)

(57) Abstract: New non-ionic surfactants in the form of polyoxyalkylene glycol hydroxy fatty acid derivatives or monoalkylated polyoxyalkylene glycol hydroxy fatty acid derivatives having a polyoxyalkylene / alkyl polyoxyalkylene chain with a chain-length of 25 - 455 repeating units and a specified substituent on the hydroxy position of the specified hydroxy fatty acid, according to the general formula (I)  $\text{CH}_3 - (\text{CH}_2)_x - \text{CH} - (\text{CH}_2)_y - \text{CO} - [-\text{O} - \text{R}_3 -]_z - \text{O} - \text{R}_1$ ,  $\text{R}_2 - \text{O}$  (I); wherein for example  $\text{R}_1$  is methyl,  $\text{R}_2$  is optionally substituted  $\text{C}_{14} - \text{C}_{22}$  acyl, alkyl, or alkenyl,  $\text{R}_3$  is ethylene,  $x$  is 2-12,  $y$  is 7-17,  $(x + y)$  is 3-19 and  $z$  is 25-57; advantageously prepared by involving an enzymatic process, formulations comprising them, their use as solubilizers and a process involving a hydrolytic enzyme for preparing them.